I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Sarah Gheuens Biography and Net Worth

Chief Medical Officer, Head of R&D of Agios Pharmaceuticals

Dr. Gheuens joined Agios in December 2019, became chief medical officer in September 2021 and took on the additional role of head of R&D in August 2022. She previously served as Agios’ head of clinical development for the genetically defined disease programs, as well as the interim head of regulatory affairs. She has been instrumental in completing the pivotal Phase 3 program for pyruvate kinase deficiency and leading simultaneous regulatory submissions to the FDA and EMA in this indication, as well as designing the pivotal programs for thalassemia, sickle cell disease and the pediatric indications. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA®. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. She serves on the Board of Directors for Viridian Therapeutics, Inc. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC, Boston, Mass., USA. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

What is Sarah Gheuens' net worth?: The estimated net worth of Sarah Gheuens is at least $1.40 million as of February 14th, 2024. Dr. Gheuens owns 33,431 shares of Agios Pharmaceuticals stock worth more than $1,400,425 as of December 18th. This net worth estimate does not reflect any other assets that Dr. Gheuens may own. Additionally, Dr. Gheuens receives an annual salary of $769,200.00 as Chief Medical Officer, Head of R&D at Agios Pharmaceuticals. Learn More about Sarah Gheuens' net worth.
How old is Sarah Gheuens?: Dr. Gheuens is currently 44 years old. There are 9 older executives and no younger executives at Agios Pharmaceuticals. The oldest executive at Agios Pharmaceuticals is Dr. Tak Wah Mak D.Sc., FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 78 years old. Learn More on Sarah Gheuens' age.
What is Sarah Gheuens' salary?: As the Chief Medical Officer, Head of R&D of Agios Pharmaceuticals, Inc., Dr. Gheuens earns $769,200.00 per year. The highest earning executive at Agios Pharmaceuticals is Mr. Brian M. Goff M.B.A., CEO & Director, who commands a salary of $1,230,000.00 per year. Learn More on Sarah Gheuens' salary.
How do I contact Sarah Gheuens?: The corporate mailing address for Dr. Gheuens and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Sarah Gheuens' contact information.
Has Sarah Gheuens been buying or selling shares of Agios Pharmaceuticals?: Sarah Gheuens has not been actively trading shares of Agios Pharmaceuticals within the last three months. Most recently, Sarah Gheuens sold 642 shares of the business's stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $25.14, for a transaction totalling $16,139.88. Following the completion of the sale, the insider now directly owns 33,431 shares of the company's stock, valued at $840,455.34. Learn More on Sarah Gheuens' trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 12/11/2024.

Sarah Gheuens Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/14/2024	Sell	642	$25.14	$16,139.88	33,431

Sarah Gheuens Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $41.89

$40.50

$42.28

50 Day Range

MA: $50.09

$38.17

$61.64

2 Week Range

Now: $41.89

$20.96

$62.58

Volume

269,089 shs

Average Volume

719,164 shs

Market Capitalization

$2.39 billion

P/E Ratio

3.69

Dividend Yield

N/A

Beta

0.8

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Sarah Gheuens Biography and Net Worth

What is Sarah Gheuens' net worth?

How old is Sarah Gheuens?

What is Sarah Gheuens' salary?

How do I contact Sarah Gheuens?

Has Sarah Gheuens been buying or selling shares of Agios Pharmaceuticals?

Who are Agios Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Agios Pharmaceuticals?